First Targeted Therapy for Dermatomyositis Succeeds in Landmark 52-Week Trial, Published in NEJM With FDA Priority Review
Brepocitinib, a first-in-class TYK2/JAK1 inhibitor, hit all primary and secondary endpoints in the largest-ever dermatomyositis trial, offering the first steroid-sparing treatment for a disease that has lacked targeted therapy for decades.
5 min read4 sources